BrainsWay Analyst Ratings
H.C. Wainwright Maintains Brainsway(BWAY.US) With Buy Rating, Maintains Target Price $16
Brainsway Receives Buy Rating From Ram Selvaraju Due to Promising Clinical Data and Market Potential
Ladenburg Thalmann Maintains Brainsway(BWAY.US) With Buy Rating, Raises Target Price to $13.4
H.C. Wainwright Maintains Brainsway(BWAY.US) With Buy Rating, Maintains Target Price $16
Brainsway Price Target Raised to $12.50/Share From $11.00 by Northland Capital Markets
Brainsway Is Maintained at Outperform by Northland Capital Markets
BrainsWay Analyst Ratings
BrainsWay Analyst Ratings
H.C. Wainwright Maintains Brainsway(BWAY.US) With Buy Rating, Maintains Target Price $16
Brainsway's Growth Trajectory: Strong Buy Rating Justified by Expansion and Strategic Developments
BrainsWay Analyst Ratings
Analysts Conflicted on These Healthcare Names: Brainsway (BWAY) and G1 Therapeutics (GTHX)
Brainsway (BWAY) Gets a Buy From Northland Securities
Buy Rating Affirmed for Brainsway: Strong Financials and Strategic Growth Drivers
BrainsWay Analyst Ratings
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $15 Price Target
BrainsWay Analyst Ratings
HC Wainwright & Co. : Maintaining the BrainsWay (BWAY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $15.00.
HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $15
Unlock the Full List